Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor plus FLAG-IDA induction for relapsed or resistant acute myeloid leukemia
2011-000971-15Phase 2Completed
- Sponsor
- PETHEMA
- Start
- Nov 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor, fludarabine, idarubicin, cytarabine and filgrastim in acute myeloid leukemia (AML), sponsored by PETHEMA. Primary endpoint: Overall remission rate. Started Nov 2011; status: completed.
02
Drugs
plerixaforfludarabineidarubicincytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-000971-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000971-15.